Selling, General, and Administrative Costs: Viatris Inc. vs Veracyte, Inc.

A Tale of Two Companies: Viatris Inc. vs Veracyte, Inc.

In the ever-evolving landscape of healthcare, understanding the financial dynamics of key players is crucial. This chart offers a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Veracyte, Inc. over the past decade.

Viatris Inc.: A Giant in the Industry

Viatris Inc., a global healthcare company, has consistently demonstrated its financial prowess. From 2014 to 2023, its SG&A expenses have surged by over 200%, peaking at approximately $4.65 billion in 2023. This growth reflects Viatris's expansive operations and strategic investments.

Veracyte, Inc.: A Rising Star

In contrast, Veracyte, Inc., a genomic diagnostics company, has shown a steady increase in SG&A expenses, growing by around 350% over the same period. By 2023, its expenses reached nearly $184 million, underscoring its commitment to innovation and market expansion.

This comparison highlights the diverse strategies and growth trajectories of these two influential companies.